Children’s OTC cold syrup pairs cough suppression, mucus thinning, and nasal decongestion
The updated DailyMed label for UP AND UP DAYTIME CHILDRENS MULTI SYMPTOM COLD describes a three-drug oral suspension designed for short-term relief of common cold symptoms in children. Each 5 mL contains dextromethorphan hydrobromide 5 mg, guaifenesin 100 mg, and phenylephrine hydrochloride 2.5 mg. In practical terms, the formulation is built to address three different symptom clusters at once: cough, chest congestion from thick mucus, and nasal stuffiness.
The label frames the product as a human OTC drug under the OTC monograph pathway and identifies the route of administration as oral. It is packaged as a 118 mL bottle and distributed by Target Corporation. The product page lists a label update date of November 10, 2026, with marketing information showing a July 19, 2024 start date. For clinicians, pharmacists, and caregivers, the central issue is not novelty but careful alignment between age, symptoms, and dosing discipline.
Three active ingredients, three distinct symptom targets
Each active ingredient plays a separate pharmacologic role. Dextromethorphan is the cough suppressant, intended to reduce the urge to cough so a child can rest. Guaifenesin is the expectorant; it helps loosen phlegm and thin bronchial secretions so mucus is easier to clear. Phenylephrine is the nasal decongestant, aimed at temporarily relieving stuffy nose and congestion due to a cold.
The label’s language is narrow and symptom-specific. It states that the product helps loosen mucus and make coughs more productive, while also temporarily relieving cough due to minor throat and bronchial irritation associated with the common cold or inhaled irritants. The combination reflects a common pediatric OTC strategy: suppress a dry or disruptive cough, thin secretions when mucus is present, and reduce nasal obstruction that can worsen nighttime symptoms. Even so, these are supportive measures, not disease-modifying therapy.
A child with a cough and a blocked nose still needs observation for the cause of the symptoms.
Age limits and dosing instructions are unusually explicit
The dosing table is direct and leaves little room for improvisation. Children 6 years to under 12 years of age should receive 10 mL every 4 hours. Children 4 to under 6 years of age should receive 5 mL every 4 hours. Children under 4 years of age should not use the product. The label also limits use to no more than 6 doses in any 24-hour period and instructs caregivers to measure only with the dosing cup provided.
Those details matter because pediatric OTC cough-and-cold products often fail in the hands of adults who estimate rather than measure. The dose volume, the interval, and the maximum daily frequency are all specified because the three active ingredients each carry their own risk if overused. The inclusion of a dedicated dosing cup is not a decorative convenience; it is part of the safety design.
The warning section draws a hard line around vulnerable children
The label warns against use in a child taking a prescription monoamine oxidase inhibitor, including certain medicines for depression, psychiatric or emotional conditions, or Parkinson’s disease, and it specifies a 2-week waiting period after stopping an MAOI. The same label urges a doctor’s input before use in children with heart disease, high blood pressure, thyroid disease, or diabetes. It also cautions against use in children whose cough occurs with too much phlegm or in those with a persistent or chronic cough such as asthma.
Those cautions reflect the pharmacology of the ingredients. Phenylephrine can be problematic in children with cardiovascular disease or hypertension because sympathomimetic decongestants may increase blood pressure or heart rate. Dextromethorphan is not meant for prolonged or unexplained cough, where the symptom may be signaling a lower airway process rather than an ordinary cold. The label’s MAOI warning is particularly important because interactions involving cough-and-cold products can become serious quickly.
Nervousness, dizziness, or sleeplessness are listed as reasons to stop use and ask a doctor.
Short duration of use is built into the labeling logic
The product is meant for brief symptomatic relief, not extended treatment. If symptoms do not improve within 7 days or occur with fever, the label directs caregivers to stop use and ask a doctor. It gives a similar instruction if cough lasts more than 7 days, comes back, or occurs with fever, rash, or persistent headache, because those features may indicate a more serious condition.
This is the key bedside implication of the label: persistent cough in a child should not be absorbed into a self-care routine indefinitely. Fever, rash, headache, or a cough that lingers beyond a week moves the problem outside the bounds of routine OTC treatment. The medicine can blunt symptoms, but it cannot replace evaluation when the pattern shifts.
Storage, formulation details, and safety handling
The label says each 5 mL contains 2 mg of sodium, and it advises storing the product at room temperature without refrigeration. The inactive ingredients include anhydrous citric acid, edetate disodium, FD&C Blue No. 1, FD&C Red No. 40, flavors, potassium citrate, propyl gallate, propylene glycol, purified water, sodium benzoate, sorbitol, sucralose, and xanthan gum. The suspension is described as red and berry-flavored.
The tamper-evident statement is also straightforward: do not use the carton if the printed inner seal under the cap is torn or missing. The label keeps the familiar OTC safeguard in place by directing users to keep the carton for future reference on full labeling. Those are small instructions on paper, but they are part of the practical safety chain once a bottle is in a household medicine cabinet.
A common formulation, but one that still demands restraint
The product is positioned as a daytime children’s multi-symptom cold medicine, and the combination of cough suppressant, expectorant, and decongestant is familiar across the pediatric OTC aisle. Familiarity can create complacency. Parents may assume that because a product is sold over the counter, it is automatically suitable for every child with a cough, yet the label draws firm boundaries around age, duration, and comorbidity.
For clinicians answering family questions, the most useful counseling point may be the simplest one: use the product only for children old enough for the labeled dose, measure it exactly as directed, and stop if symptoms persist or evolve. In a child with wheeze, high fever, chronic cough, or a cough with heavy mucus, the diagnosis deserves more attention than a syrup can provide. The label leaves no ambiguity on that point, even if the bottle itself is marketed for routine home use.